ADCYAP1 and diabetic retinopathy: PACAP treatment effectively reduced neuronal cell loss in the ganglion cell layer (GCL), preserved cone cell integrity, and maintained dopaminergic amacrine cell numbers, reinforcing its strong neuroprotective potential in diabetic retinopathy (DR).